These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 80134)

  • 41. Increased plasma concentration of cross-linked fibrin polymers in acute myocardial infarction.
    Francis CW; Connaghan DG; Scott WL; Marder VJ
    Circulation; 1987 Jun; 75(6):1170-7. PubMed ID: 3568326
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparison of methods for detecting soluble fibrin in plasma. An in vitro study.
    Halvorsen S; Skjønsberg OH; Ruyter R; Godal HC
    Thromb Res; 1990 Feb; 57(4):489-97. PubMed ID: 2326770
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [A comprehensive laboratory evaluation of changes in the fibrinogen molecule in the diagnosis of acquired coagulopathy conditions].
    Siatkovskiĭ VA; Azarova LA; Vasilenko PL
    Lab Delo; 1989; (8):45-8. PubMed ID: 2477628
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Fibrinogen and fibrin derivatives in traumatized patients: relation to injury severity and posttraumatic pulmonary dysfunction.
    Sørensen JV; Jensen HP; Rahr HB; Borris LC; Lassen MR; Fedders O; Haase JP; Knudsen F
    Haemostasis; 1993; 23(2):91-7. PubMed ID: 8365691
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A positive ethanol gelation test associated with high plasma fibrinogen concentration - evidence for soluble fibrin. An experimental study in rabbits.
    Slaastad RA; Jakobsen E; Godal HC
    Scand J Haematol; 1975 Oct; 15(3):192-200. PubMed ID: 1198062
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Fibrinogen-fibrin degradation products.
    Kwaan HC
    Ann Clin Lab Sci; 1980; 10(3):234-7. PubMed ID: 7396389
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Specific identification of urinary fibrinogen, fibrinogen degradation products, and cross-linked fibrin degradation products in renal diseases and after renal allotransplantation.
    Scott WL; Francis CW; Knutson DW; Marder VJ
    J Lab Clin Med; 1986 Jun; 107(6):534-43. PubMed ID: 3519810
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Urinary fibrin and fibrinogen degradation products and the origin of hematuria.
    Tsukahara H; Hiraoka M; Sudo M; Okada T; Morikawa K; Kuroda M
    Acta Paediatr Jpn; 1992 Oct; 34(5):525-9. PubMed ID: 1442024
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Automated nephelometry of fibrinogen: analytical performance and observations during thrombolytic therapy.
    Hoffmann JJ; Verhappen MA
    Clin Chem; 1988 Oct; 34(10):2135-40. PubMed ID: 3168233
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Fibrinogen/fibrin degradation products (FDP/fdp). Characterization, anticoagulant activity, and influence on laboratory assays.
    Arnesen H
    J Oslo City Hosp; 1977 Jun; 27(6):69-80. PubMed ID: 142131
    [No Abstract]   [Full Text] [Related]  

  • 51. Reactivity of soluble fibrin assays with plasmic degradation products of fibrin and in patients receiving fibrinolytic therapy.
    McCarron BI; Marder VJ; Francis CW
    Thromb Haemost; 1999 Dec; 82(6):1722-9. PubMed ID: 10613661
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Study on high molecular weight fibrinogen/fibrin complex (HMWFC) (author's transl)].
    Suzuki S; Matsui N
    Rinsho Ketsueki; 1979 Aug; 20(8):901-9. PubMed ID: 502006
    [No Abstract]   [Full Text] [Related]  

  • 53. Deposits of fibrin and plasma proteins in the normal human placenta. An immunofluorescence study.
    Moe N
    Acta Pathol Microbiol Scand; 1969; 76(1):74-88. PubMed ID: 4187102
    [No Abstract]   [Full Text] [Related]  

  • 54. Derivatives of fibrinogen and fibrin during defibrase therapy. Separation of high and low molecular weight derivatives of fibrinogen and fibrin by agarose gel filtration.
    Asbeck F; Lechler E; Martin M; van de Loo J
    Haemostasis; 1974; 3(5-6):340-7. PubMed ID: 4468232
    [No Abstract]   [Full Text] [Related]  

  • 55. Mechanisms for elevated fibrin/fibrinogen degradation products in acute experimental pulmonary embolism.
    Cade J; Hirsh J; Regoeczi E
    Blood; 1975 Apr; 45(4):563-8. PubMed ID: 1115842
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A diazophenylthio-ether-IgG probe for analysing fibrin- and fibrinogen-related antigens.
    Kruskal JB; Maeder DL; Purves LR; Franks JJ; Kirsch RE
    S Afr Med J; 1987 Feb; 71(4):211-7. PubMed ID: 3824087
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A mechanism for fibrin monomer aggregation based on a kinetic study.
    Usero JL; Burguillo FJ; Izquierdo C; Del Arco A; Herraez MA
    Int J Biochem; 1984; 16(5):553-9. PubMed ID: 6724108
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Elevated levels of soluble fibrin in patients with venous thromboembolism.
    Tsuji A; Wada H; Matsumoto T; Abe Y; Ota S; Yamada N; Sugiyama T; Sudo A; Onishi K; Nakatani K; Uchida A; Ito M; Suzuki K; Nobori T
    Int J Hematol; 2008 Nov; 88(4):448-453. PubMed ID: 18836793
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Critical evaluation of new methods for studying fibrin degradation products].
    Prisco D
    Recenti Prog Med; 1989 May; 80(5):263-7. PubMed ID: 2669062
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Biochemical study of adduct synthesis between fibrin monomers and elastin.
    Martin MT; Lefebvre F; Rabaud M; Graves PV
    Biomaterials; 1988 Nov; 9(6):519-24. PubMed ID: 3224139
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.